Theriva Biologics fails to convene special meeting due to lack of quorum; will reschedule

Theriva Biologics, Inc.

Special Meeting on June 5, 2026, lacked quorum; meeting not convened.
Company will call a new meeting to seek stockholder approval for warrant exercise proposal.
Under Inducement Agreement (Oct 2025), seeks approval for issuance of up to 16,184,560 shares upon warrant exercise.
Unless waived, must call meeting every 60 days until approval obtained or warrants expire.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.